Search This Blog

Wednesday, January 8, 2020

UnitedHealthcare drops Vascepa from Preferred List; Amarin down

Amarin (AMRN -2.7%) slips on below-average volume in early trade. UnitedHealth Group’s UnitedHealthcare has categorized Vascepa (icosapent ethyl) as “non-preferred” for 2020 while maintaining Lovaza (omega-3-acid ethyl esters) on its Preferred List.
The latter is GlaxoSmithKline’s branded version, although it is off-patent. The FDA OK’d Teva Pharmaceutical Industries’ generic version in April 2014, for example.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.